Gene Signal in talks for a partner for eye disease drug – GlobalPost

Gene Signal in talks for a partner for eye disease drug
GlobalPost
Privately-held Gene Signal is looking to muscle in on the lucrative market for treating wet age-related macular degeneration (AMD) currently dominated by Roche’s Lucentis and Regeneron’s Eylea. Unlike Lucentis and Eylea, which must be injected into the …

and more

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment